Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behçet’s disease

Naomi Tsuchida1,2, Yohei Kirino2*, Yutaro Soejima2, Masafumi Onodera3, Katsuhiro Arai4, Eiichiro Tamura3, Takashi Ishikawa3, Toshinao Kawai3, Toru Uchiyama3, Shigeru Nomura5, Daisuke Kobayashi6, Masataka Taguri7, Satomi Mitsuhashi1, Takeshi Mizuguchi1, Atsushi Takata1, Noriko Miyake1, Hideaki Nakajima2, Satoko Miyatake1,8 and Naomichi Matsumoto1*

Abstract

Background: Haploinsufficiency of A20 (HA20) is caused by loss-of-function TNFAIP3 variants. Phenotypic and genetic features of HA20 remain uncertain; therefore, the clinical distinction between HA20 and Behçet’s disease (BD) requires clarification.

Methods: We have collected 12 Japanese BD-like families. Probands of these families were analyzed by whole exome sequencing (WES) and subsequent Sanger sequencing. Clinical features were compared between 54 HA20 patients (including previously reported and new cases) and 520 Japanese BD patients.

Results: We identified c.1434C>A:p.(Cys478*) in one family and a 236 kb deletion at 6q23.3 containing TNFAIP3 in another family. Four HA20 patients in the two families presented with childhood-onset recurrent oral and genital ulcers and were initially diagnosed and treated as BD. Consistent with the clinical features of HA20, recurrent, refractory fever attacks (three of four patients), and digestive ulcers (two of the four patients) were observed. A comparison of clinical features between HA20 patients and cohorts of BD patients revealed several critical features specific to HA20. These were early-onset, familial occurrence, recurrent fever attacks, gastrointestinal involvement, and infrequent ocular involvement.

Conclusions: We identified a novel nonsense variant and deletion of the entire TNFAIP3 gene in two unrelated Japanese HA20 families. Genetic screening of TNFAIP3 should be considered for familial BD-like patients with early-onset recurrent fevers.

Keywords: TNFAIP3, Haploinsufficiency of A20, Behçet’s disease, Whole exome sequencing, Autoinflammatory
Introduction
Behçet’s disease (BD) is an inflammatory disease of unknown etiology, with recurrent oral and genital ulcers, uveitis, skin inflammation, enterocolitis, and inflammation in other organs [1,2]. Genome-wide association studies show that common genetic factors are involved in the pathogenesis of the disease [3]. In addition, rare monogenic conditions manifest BD-like phenotypes [4,5]. Heterozygous loss-of-function TNFAIP3 variants identified in BD-like patients are now classified as haploinsufficiency of A20 (HA20) [5]. Unlike typical BD, HA20 presents various autoinflammatory and/or autoimmune symptoms in addition to a BD-like phenotype, indicating that there may be HA20-specific symptoms compared with those of BD [5–15]. It is important to accumulate HA20 patients to understand its full clinical spectrum. We here report a novel heterozygous TNFAIP3 variant and a copy number variation found in two unrelated families. Clinical features of HA20 and BD are discussed.

Materials and methods
Patients
A series of families, each with more than two or more patients with BD-like symptoms, were recruited. All patients met the diagnostic criteria (revised in 1987) of the Behçet’s Disease Research Committee, Ministry of Health, Labor and Welfare of Japan [16]. The study protocol was approved by the institutional review boards of Yokohama City University School of Medicine and the National Center for Child Health and Development, and written informed consent was obtained from all patients or their parents. For comparison of clinical features between HA20 and BD, we used a previously described BD cohort from the Yokohama City University Hospital [17].

Whole-exome sequencing
Peripheral-blood leukocytes from affected individuals and their families were collected. Genomic DNA was extracted using QuickGene-610L (Fujifilm, Tokyo, Japan) according to the manufacturer’s protocol. Genomic DNA was sheared and captured using a SureSelect Human All Exon V6 Kit (Agilent Technologies, Santa Clara, CA, USA) and sequenced on a HiSeq2500 or Novaseq 6000 system (Illumina, San Diego, CA, USA) with 101-bp paired-end reads. Exome data processing, variant calling, and annotation were performed as previously described [18]. In brief, reads were aligned to GRCh37 with Novoalign (http://www.novocraft.com/), and PCR duplicates were removed using Picard (http://broadinstitute.github.io/picard/). Local realignments around indels and base quality-score recalibration were performed using the Genome Analysis Toolkit (GATK). Variants were called by the GATK UnifiedGenotyper and filtered according to GATK Best Practices (version 3) (https://software.broadinstitute.org/gatk/). The common variants registered in dbSNP137 (minor allele frequency ≥0.01) without known clinical associations were excluded from further analysis. Included variants were annotated using ANNOVAR (http://annovar.openbioinformatics.org/). The mean depth of coverage against the RefSeq coding sequence (CDS) was 64.7×, and 97.0% of CDS was covered by 10 reads or more. To identify causal variants, the obtained variants were filtered according to the following exclusion criteria: (a) variants with a >1% minor allele frequency in the Exome Aggregation Consortium database (ExAC, Cambridge, MA, http://exac.broadinstitute.org/), (b) variants observed in 575 Japanese in-house control exomes, and (c) synonymous variants. We evaluated the remaining variants under the assumption of autosomal dominant inheritance and particularly focused on rare variants in genes known to be involved in autoinflammatory diseases. Variants and their familial segregation were confirmed using Sanger sequencing.

Copy number variants (CNVs) were examined using whole-exome sequencing (WES) data as previously described [19,20]. Two algorithms were used: the eXome-Hidden Markov Model (XHMM) [21] and a program based on the relative depth of coverage ratios developed by Nord et al. [22], hereafter called Nord’s method. In brief, XHMM detects CNVs from entire coding regions by analyzing normalized raw exome read depth data with principal component analysis (PCA) and the hidden Markov model. Nord’s method evaluates targeted genes using raw exome read depth data. Candidate CNVs were validated by quantitative PCR.

Reverse transcription polymerase chain reaction
Lymphoblastoid cell lines derived from patient 1 and 2 were grown in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum, tylosin and antibiotic-antimycotic solution at 37°C in a 5% CO2 incubator. After incubation with dimethyl sulfoxide (DMSO) (as vehicle control) or 30 μM cycloheximide (CHX) to observe the preventive effects of CHX on nonsense-mediated mRNA decay (NMD) for 4 h, total RNA was extracted using an RNasy Plus Mini Kit (QIAGEN, Hilden, Germany). cDNA was synthesized from 2.5 μg of total RNA using random hexamers and the SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, California). The control cDNA was isolated from a patient with a different disease (early-onset epilepsy). PCR included 24 cycles with specific primers for the exon 6–7 boundary and the exon 7–8 boundary (available on request). PCR products electrophoresed in 2% agarose gel were stained with ethidium bromide. PCR was conducted with the autosomal internal control locus (ACTB). RT-PCR products were sequenced by the Sanger method.
Statistical analysis
Statistical analysis was performed with SPSS version 22 (IBM Japan, Tokyo, Japan). Categorical variables were analyzed using the chi-square test. Continuous variables were examined using Student's t test. A p value less than 0.05 was considered statistically significant.

Results
Overview of the studied families
Twenty-five patients from 12 families were collected (data not shown). In each family, WES was performed on the proband and on other selected family members. Two novel \( \text{TNFAIP3} \) pathogenic changes were found in two families (16.7%, 2 of 12).

Identification of \( \text{TNFAIP3} \) variants
WES was performed on the probands (patient 1 from family 1 and patient 3 from family 2) and on the parents of patient 3 (Fig. 1a, b).

In patient 1, we identified a novel nonsense variant, c.1434C>A:p.(Cys478*), in \( \text{TNFAIP3} \) (NM_006290.3). This variant was absent from ExAC, in-house exome controls, and Infevers (an online database for autoinflammatory mutations, https://infevers.umai-montpellier.fr/web). We detected no variants in other genes associated with autoinflammatory diseases. Sanger sequencing confirmed the same variant in the affected sister (patient 2) (Fig. 1a). To observe mutational effects of this variant, RT-PCR was performed using total RNA extracted from lymphoblastoid cell lines derived from patients 1 and 2. RT-PCR products were electrophoresed and the band intensity in DMSO-treated cells from affected patients was weak compared to that from DMSO-treated control cells. Band intensity was stronger after CHX treatment (Fig. 2a). Direct sequencing of PCR products showed that CHX treatment increased the presence of the mutant allele compared with DMSO treatment (Fig. 2b). These results indicate that this nonsense variant may be subjected to NMD [23]. Based on the American College of Medical Genetics and Genomics guidelines [24], this variant is classified as pathogenic (PVS1, PM2, PP3, PP4).

In family 2, no candidate single nucleotide variant or small indel was found in any gene associated with autoinflammatory diseases. WES-based CNV analysis identified a 236 kb deletion at 6q23.3 [chr6:138192201-138428412 (GRCh37/hg19)] involving \( \text{TNFAIP3} \) and \( \text{PERP} \) in patients 3 and 4 (Figs. 1b and 3a, b). Several CNVs involving \( \text{TNFAIP3} \) were reported in the Database of Genomic Variants (DGV) (http://dgv.tcag.ca/dgv/app/), ExAC, and DECIPHER (http://decipher.sanger.ac.uk), but these CNVs are not common in the Japanese population. Five patients in DECIPHER have a > 4 Mb deletion involving \( \text{TNFAIP3} \).
and more than 30 genes. Intellectual disability was recorded for two of these patients, but no information regarding inflammatory status was recorded. In addition, four healthy individuals registered in DGV and ExAC have deletions involving \textit{TNFAIP3}; three cases have a \textit{TNFAIP3} deletion only and the other case has a 934 kb deletion involving \textit{TNFAIP3} and four other genes. Familial HA20 clearly indicates reproductive fitness \cite{5–7, 11–14}, and the penetrance of \textit{TNFAIP3} abnormality could be variable. Recently, a HA20 patient was described with a 13-Mb CNV encompassing \textit{TNFAIP3} and another 52 genes (Fig. 3c) \cite{8}. Meanwhile, germline \textit{PERP} pathogenic variants have never been reported in any human diseases. In the animal model, \textit{Perp} knockout mice showed postnatal lethality and defects in the skin and other ectodermal derivatives, resembling ectodermal dysplasia syndrome \cite{25}. \textit{Perp} heterozygous mice showed no expected clinical phenotypes \cite{26}. Patients in family 2 showed no signs of ectodermal dysplasia. There are small numbers of truncating variants in a healthy public database, ExAC, and DGV. Quantitative PCR confirmed the deletion in the affected proband and her mother (Fig. 1b). Considering these findings, the phenotype of the affected patients in family 2 can be explained by \textit{TNFAIP3} haploinsufficiency.

### Clinical features

The clinical features of the two families with \textit{TNFAIP3} variants are summarized in Table 1.

#### Family 1

Patient 1 (III-2 in Fig. 1a) is a 35-year-old male who is the second child of non-consanguineous Japanese
Fig. 3 (See legend on next page.)
parents. He presented with fever and lymphadenopathy at the age of 6. He was diagnosed with BD at 7 years of age because of recurrent oral and perianal ulcers and was prescribed with oral prednisolone (PSL). He had recurrent episodes of high-grade fever (up to 39 °C) associated with lymphadenopathy, pharyngalgia, and nausea. PSL dosage was adjusted according to the patient’s condition, and the withdrawal of PSL was difficult. He did not show any ophthalmological or neurological symptoms. He is currently treated with PSL (12.5 mg/day) and colchicine (1.0 mg/day).

Patient 2 (III-3 in Fig. 1a) is the proband’s younger sister. She had oral and genital ulcers at 12 and 15 years of age, respectively. At the age of 19, she presented with fever, oral, and genital ulcers, and she was diagnosed with BD. At 25 years of age, she was hospitalized due to fever and erythema nodosum and she was treated with PSL and colchicine. Thereafter, she was treated with low-dose PSL (5–10 mg/day) and colchicine, but they were ineffective in preventing further attacks. At 29 years of age, she presented with Raynaud’s phenomenon. Skin biopsy of erythema nodosum (Fig. 4a) showed similar pathological findings to cutaneous periarteritis nodosa or thrombophlebitis. Gastrointestinal endoscopy revealed multiple ulcers in the stomach and colon, which were not typical of intestinal BD (Fig. 4d, e). Torso CT imaging showed hepatosplenomegaly and generalized lymphadenopathy (Fig. 4f). She had bouts of recurrent fever, erythema nodosum, cervical lymphadenopathy, and abdominal pain lasting 2 weeks several times a year, but these symptoms subsided spontaneously without any

Table 1 Summary of patients with TNFAIP3 variants

| Family | Patient | Family 1 | Patient 1 | Patient 2 | Family 2 | Patient 3 | Patient 4 |
|--------|---------|----------|-----------|-----------|----------|-----------|-----------|
| Age    | 35 years| 34 years | 12 years  | 42 years  |
| Gender | M       | F        | F         | F         |
| Detected variant | TNFAIP3 (NM_006290.3) c.1434C>A:p.(Cys478*) | chr6:138192201-138428412 (GRCh37/hg19) deletion (including TNFAIP3) |
| Initial symptoms | Fever, lymphadenopathy | Oral ulcer, genital ulcer | Periodic fever | Oral ulcer |
| Symptom onset | 6 years | 12 years | 2 months  | 1 year    |
| Age at diagnosis | 7 years | 19 years | 11 years  | 16 years  |
| Fever   | +       | +        | +         | –         |
| Lymphadenopathy | +       | +        | +         | +         |
| Oral ulcers | +      | +        | +         | +         |
| Genital ulcers | +      | +        | +         | +         |
| Skin lesions | –      | Erythema nodosum, pernio-like rash | –         | Folliculitis |
| Ophthalmic signs | –      | –        | Acute anterior uveitis | –         |
| Digestive signs | Nausea | Abdominal pain, vomiting, digestive ulcers, colitis | Abdominal pain, diarrhea, bloody stools, weight loss, digestive ulcers | Abdominal pain |
| Musculoskeletal signs | –      | –        | –         | –         |
| Others  | Pharyngalgia | Raynaud’s phenomenon | Pharyngalgia, enlarged tonsil | Thyroiditis |
| Treatment | PSL, colchicine | Symptomatic treatment, PSL, colchicine | Colchicine, cimetine, PSL, mesalazine, NSAIDs, MTX, corticosteroid eye drops | Levothyroxine |

NSAIDs non-steroidal anti-inflammatory drugs, MTX methotrexate, PSL prednisolone
treatment. At 33 years of age, a CT scan confirmed persisting hepatosplenomegaly and lymphadenopathy (Fig. 4g) and she presented with a severe pernio-like rash in the cold season (Fig. 4b, c). Aspiration biopsy of cervical lymph nodes showed no signs of malignant lymphoma.

The proband’s elder brother (III-1 in Fig. 1a) had multiple episodes of hospitalization due to the fever of unknown origin, but detailed clinical information is not available. The proband’s father (II-5 in Fig. 1a) had recurrent oral ulcers. At 58 years of age, he presented with intractable skin lesions and poly-lymphadenopathy. Lymph node biopsy showed reactive inflammation, but no immuno-suppressants were needed for treatment. At 59 years of age, he was diagnosed with amyotrophic lateral sclerosis and passed away from aspiration pneumonia at the age of 60. The proband’s mother (II-6 in Fig. 1a) had no BD-like symptoms and passed away from colon cancer. The proband’s aunt on the paternal side (II-2 in Fig. 1a) had recurrent febrile episodes, but details are unavailable.

**Family 2**

Patient 3 (III-1 in Fig. 1b) is a 12-year-old girl who is the first child of non-consanguineous Japanese parents. At 2 months of age, she presented with 38–39°C fever accompanied by abdominal pain, diarrhea, ankle arthralgia, oral ulcers, pharyngalgia, and an enlarged tonsil. Febrile attacks were recurrent every 1–2 weeks and resolved within 4 days. She presented with perianal ulcers (at 4 years old), bloody stool, and weight loss (at 5 years old), but colonoscopy did not identify any abnormality. At 9 years of age, she was
prescribed with naproxen and methotrexate (MTX) because of left ankle arthritis, but MTX was stopped because of abdominal pain. She was treated with colchicine and mesalazine for abdominal pain, but they were not effective. At 10 years of age, she was suspected of having a periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome and was treated with cimetidine, which contributed to a reduction in the number of febrile attacks. Gastrointestinal and capsule endoscopy revealed multiple ulcers throughout the intestinal tract (Fig. 5), and mesalazine was re-administered. Histopathology of ulcer biopsies showed infiltration of lymphocytes and plasma cells. There was no evidence of granuloma, cryptitis, or crypt abscess, and the findings were thought to indicate nonspecific chronic inflammation. At 11 years of age, bilateral non-granulomatous acute anterior uveitis was revealed by ophthalmologic examination and diagnosed as BD. She did not show any neurodevelopmental delay. Currently, she experiences genital ulcers and has been treated with colchicine (400 mg/day), cimetidine (1.0 mg/day), and corticosteroid eye drops. The severity of abdominal pain is milder than before and fever is less frequent.

Patient 4 is the proband’s mother (II-2 in Fig. 1b). At 1 year of age, she presented with intractable oral ulcers and was twice admitted to hospital for dehydration. At 12 years of age, she had oral ulcers during orthodontic
treatment. At 15 years of age, she presented with genital ulcers and abdominal pain. At 16 years of age, she was diagnosed with BD. Colonoscopy at 18 years of age did not show any abnormality. At 34 years of age, she showed folliculitis at the lower limbs. At 35 years of age, she was diagnosed with Hashimoto disease and was treated with levothyroxine. She presented fever with tonsillitis and lymphadenitis several times a year since her childhood, but they were not apparently periodic nor present in prolonged courses. She did not show any ophthalmological, neurological, and musculoskeletal symptoms.

The other maternal relatives (I-1, I-2, II-3, and II-4 in Fig. 1b) had no BD-like symptoms.

Comparison of HA20 and BD clinical features

Our study raises the possibility that some BD patients may actually be HA20 patients because our two HA20 families had long been diagnosed and treated as BD. If BD and HA20 treatment strategies are different, the precise diagnosis of HA20 and differentiation from typical BD is important. We utilized the data from a large cohort of BD patients accumulated at our institute [17] to conduct a comparison of the clinical features of HA20 and BD.

Table 2 summarizes the clinical features of 54 cases with TNFAIP3 variants (50 previously reported cases [5–15] and the four cases described here) and compares these with those of our 520 archived BD cases. Consistent with previous reports [6–8], recurrent oral and genital ulcers, skin lesions, gastrointestinal, and musculoskeletal involvement were frequent in HA20. These clinical symptoms are similar to those of BD, and it is reasonable that 51.9% of HA20 cases were initially diagnosed as BD. However, HA20 showed significantly earlier onset (6.0 ± 6.5 years) and higher familial occurrence (60.0% in pedigrees). Clinically, HA20 showed significantly more recurrent fever (72.5%), gastrointestinal involvement (41.5%), and less eye involvement (9.6%) compared with BD. Among HA20 patients with gastrointestinal involvement, 18 of 22 patients (81.8%) showed gastrointestinal ulcers, including two cases with BD-typical ulcers, and ulcers were distributed

Table 2: Clinical features of haploinsufficiency of A20 (HA20) and Behçet’s disease (BD)

| Characteristics                        | HA20 (n = 54) (%) | BD (n = 520) (%) | p     | Odds ratio | 95% CI |
|----------------------------------------|-------------------|-----------------|-------|------------|--------|
| Age at onset (years) (mean ± SD)       | 6.0 ± 6.5         | 36.4 ± 12.3     | < 0.001 | 624.75     | 188.92 | 2065.98 |
| Childhood onset (< 16 years old)       | 49/53 (92.5)      | 10/520 (1.9)    | < 0.001 | 624.75     | 188.92 | 2065.98 |
| Observation period (years) (mean ± SD) | 15.5 ± 14.9       | 13.7 ± 12.0     | 0.37   |            |        |        |
| Gender male                            | 20/54 (37.0)      | 241/520 (46.3)  | 0.19   | 0.68       | 0.38   | 1.22   |
| Familial                               | 15/25 (60.0)      | 19/332 (5.7)    | < 0.001 | 24.71      | 9.80   | 62.29  |
| Recurrent fever                         | 37/51 (72.5)      | 39/364 (10.7)   | < 0.001 | 22.02      | 10.99  | 44.30  |
| Oral ulcer                             | 46/52 (88.5)      | 518/520 (99.6)  | < 0.001 | 0.03       | 0.01   | 0.15   |
| Genital ulcer                          | 34/52 (65.4)      | 372/520 (71.5)  | 0.35   | 0.75       | 0.41   | 1.37   |
| Eye involvement                        | 5/52 (9.6)        | 330/520 (63.5)  | < 0.001 | 0.06       | 0.02   | 0.16   |
| Skin involvement                       | 28/52 (53.8)      | 461/520 (88.7)  | < 0.001 | 0.15       | 0.08   | 0.27   |
| Arthritis                              | 21/54 (38.9)      | 245/520 (47.1)  | 0.25   | 0.71       | 0.40   | 1.27   |
| Gastrointestinal involvement           | 22/53 (41.5)      | 78/520 (15.0)   | < 0.001 | 4.02       | 2.21   | 7.31   |
| Vascular involvement                   | 7/53 (13.2)       | 41/520 (7.9)    | 0.18   | 1.78       | 0.76   | 4.19   |
| CNS involvement                        | 5/53 (9.4)        | 57/520 (11.0)   | 0.73   | 0.85       | 0.33   | 2.21   |
| Autoimmune diseases                    | 26/54 (48.1)      | 36/520 (9.1)    | < 0.001 | 9.26       | 4.91   | 17.46  |
| Anti-nuclear antibody (≥160×)          | 3/12 (25.0)       | 15/288 (5.2)    | 0.03   | 6.07       | 1.49   | 24.76  |
| HLA-B51                                | 3/11 (27.3)       | 195/408 (47.8)  | 0.23   | 0.41       | 0.11   | 1.57   |
| Past/current colchicine use            | 29/53 (54.7)      | 374/518 (72.2)  | 0.008  | 0.47       | 0.26   | 0.83   |
| Past/current bDMARDs use               | 19/53 (35.8)      | 89/520 (17.1)   | 0.001  | 2.71       | 1.48   | 4.96   |
| Fulfilling ISG criteria for BD         | 23/54 (42.6)      | 468/520 (90.0)  | < 0.001 | 0.08       | 0.05   | 0.15   |

BD, Behçet’s disease; bDMARDs, biological disease modifying anti-rheumatic drugs; CNS, central nervous system; HA20, haploinsufficiency of A20; ISG, International Study Group. Significant results are highlighted in italics.

*Includes previously reported [5–15] and current cases with genetically confirmed HA20.

†Age at “symptom onset” for HA20 and “diagnosis” for BD.

‡Ratio of the pedigree with familial aggregation among all families.

§Cases with gastrointestinal lesions revealed by imaging (endoscope, CT).

∥Autoimmune diseases including systemic diseases (rheumatic diseases) and organ-specific diseases (e.g., Hashimoto disease, insulin-dependent diabetes, etc.).

*Fulfilling ISG criteria for BD.

Analyzed using the unpaired t test. Other variables were analyzed using the chi-square test.
in various regions of the digestive tract. Detailed information and images of gastrointestinal lesions were not available for all previous cases, and thus, it was difficult to investigate additional features. Some patients did not undergo a gastrointestinal scan, but 34 of the 53 HA20 patients presented with some gastrointestinal symptoms. The positive rate of HLA-B51 in HA20 patients was lower (27.3%) than that in BD (47.8%), but because the majority of HA20 has been reported in European populations whose HLA-B51 positive rate is lower than that of Japanese populations, it is uncertain whether HLA-B51 affects the HA20 phenotype. Concomitant autoimmune disease and positive autoantibodies were suggested in previous reviews [6, 7], and indeed, there was a trend for this compared with our BD cohort, but analysis of additional HA20 cases is needed for confirmation.

Considering the difference in ethnicity among HA20 and our BD cohort, we conducted sub-analysis of confined Japanese patients with HA20 and BD, which revealed similar results (Additional file 1: Table S1), while it is well known that adult and pediatric BD exhibit distinct clinical features. Because HA20 showed more childhood-onset, we conducted an additional comparative analysis of HA20 and pediatric BD using data from the Pediatric Behçet’s disease (PEDBD) study [27]. Additional file 2: Table S2 summarizes clinical features. Similar to comparison with adult BD cohort, HA20 showed significantly more familial occurrence, fever, gastrointestinal involvement, and less eye involvement. HA20 cases showed less fulfilling ISG and PEDBD criteria for BD. Our conclusion did not alter by the additional analyses.

**Discussion**

In the current study, we identified a novel nonsense variant and a novel CNV in TNFAIP3 in two families who had been diagnosed as BD. We then compared clinical features in HA20 and BD patients and identified several key features differentiating HA20 from BD. Analyzing TNFAIP3 is important if HA20 is suspected in BD-like patients.

Comparison of the clinical features between HA20 and BD cohorts revealed that some features are shared between HA20 and BD as previously reported [6–8]; recurrent oral and genital ulcers, and skin, eye, musculoskeletal, and gastrointestinal involvement were commonly seen in both HA20 and BD. Moreover, we identified features that are more likely to occur in HA20 than BD: early-onset disease, family history, recurrent fever, frequent gastrointestinal involvement, and less frequent eye involvement. Applying these criteria, the clinical characteristics of our four patients were more consistent with HA20 than BD.

Only a few years have passed since HA20 was first recognized as a distinct disease; therefore, a diagnosis of HA20 is not easy. Many clinical features of HA20 are similar to those of BD, and about half of HA20 cases were initially diagnosed as BD [5–7, 12–14]. However, HA20 is not commonly seen in adult-onset BD (1/768, 0.13%) [5], and our clinical comparison of HA20 and BD indicates further differences (Table 2); therefore, HA20 analysis may only be required in cases with HA20-specific signs, including familial occurrence, early-onset, and/or recurrent fever. This distinction will be important if treatment strategies specific to HA20 will be established. Although anti-cytokine therapy was effective in several cases, there were cases in which only follow-up or low-dose steroids and colchicine were needed. Disease severity and treatment responses vary; therefore, the accumulation of cases with TNFAIP3 variants is needed to elucidate the pathophysiology and treatment strategies for HA20.

A patient with a 13 Mb deletion involving TNFAIP3 presenting autoinflammation and psychomotor and growth delay was reported [8]. This 13 Mb CNV contains at least 53 protein-coding genes, six of which are linked to the immune system, suggesting that some of these genes affect the phenotype of patients, in addition to TNFAIP3. In contrast, the 236 kb CNV in family 2 included only two genes (Fig. 3c), and the affected proband symptoms were consistent with HA20. Therefore, TNFAIP3 haploinsufficiency resulted in familial HA20. Next-generation sequencing (NGS) data is useful to detect small CNVs that might be difficult to identify by conventional microarray analysis [19–22]. Patient 3 in family 2 did not show neurodevelopmental delay; therefore, microarray and karyotype analysis was not performed. Such a 236 kb deletion may be easily overlooked if careful CNV investigation is not considered.

Finally, there are some limitations to this study. We have investigated mainly familial BD cases by WES analysis but no sporadic cases. Some sporadic HA20 cases with variable phenotypes have been reported [5, 8–12]. Therefore, we may have underestimated the incidence of HA20 among our sporadic BD cohort. It was, however, reported that targeted resequencing of 384 sporadic Japanese BD patients identified no TNFAIP3 variants [5]. We also detected only two families with HA20 among our 12 BD-like families. Recently, some autoinflammatory-associated genes other than TNFAIP3 were identified in familial cases with overlapping phenotypes [4, 28, 29]. There must be other genetic abnormalities in other BD families, and they require further thorough investigation. Although BD has a complex, multifactorial genetic etiology, elucidation of the pathophysiology of monogenic autoinflammatory diseases might help to determine the disease mechanisms of BD. Lastly, as our BD cohort is mostly Japanese (98.5%), it is likely that HA20-specific features, relative to BD, may be different in different populations.
In conclusion, we identified a novel TNFAIP3 single nucleotide variant and a CNV involving TNFAIP3 in two Japanese families. In patients with HA20-specific features, TNFAIP3 analysis should be considered, including CNV analysis.

Additional files

- **Additional file 1:** Table S1. Clinical features of Japanese haploinsufficiency of A20 (HA20) and Japanese Behcet’s disease (BD). (DOCX 22 kb)
- **Additional file 2:** Table S2. Clinical features of haploinsufficiency of A20 (HA20) and the Pediatric Behcet’s disease (PEDBD). (DOCX 21 kb)

Abbreviations

BD: Behcet’s disease; CNV: Copy number variation; ExAC: Exome Aggregation Consortium database; GATK: Genome Analysis Toolkit; HA20: Haploinsufficiency of A20; IBD: Inflammatory bowel disease; MTX: Methotrexate; NGS: Next-generation sequencing; NMD: Nonsense-mediated mRNA decay; PFAPA: Periodic fever, aphthous stomatitis, pharyngitis, and adenitis; WES: Whole-exome sequencing; XHMM: eXome-Hidden Markov Model

Acknowledgements

We thank the patients and their families for their participation in this study. We are also grateful to Ms. Nobuko Watanabe, Ms. Mai Sato, and Ms. Kaori Takabe from the Department of Human Genetics, Yokohama City University Graduate School of Medicine, for their excellent technical assistance. The genetic analysis was partially performed by the Initiative on Rare and Undiagnosed Diseases in Pediatrics (IRUD-P) from the Japan Agency for Medical Research and Development. We thank Jeremy Allen, PhD, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.

Authors’ contributions

NT performed experiments, analyzed data, and wrote the manuscript. YS, MO, TI, ET, TK, TU, KA, SN, and DK examined patients and collected data. MT interpreted the data. SM, TM, AT, NM, HN, and SM coordinated the study and critically revised the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by grants from the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research [JP26713036 (YK), JP17H01539 (NMa), JP16H05357 (NMI), JP16K06254 (AT)], the Japan Agency for Medical Research and Development [JP16ek0109280, JP16dk0107000, JP16ek0109300, JP16ek0109348, JP18ek020201 (NMa)], the Yokohama Foundation for Advancement of Medical Science (YK, NT), The Naito Memorial Foundation (YK), The Uehara Memorial Foundation (YK), the Japanese Rheumatic Disease Foundation (YK), the Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics (SMiy), the Ministry of Health, Labour and Welfare (NMa), and the Takeda Science Foundation (NMa).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

The study protocol and genetic analyses were approved by the Yokohama City University Ethical Board (A121129002, A141127010) and the National Center for Child Health and Development (1802). Written informed consent was obtained for the use of all human samples.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Department of Human Genetics, Yokohama City University Graduate School of Medicine, 3-9 Fukaura, Kanazawa-ku, Yokohama 236-0004, Japan.
2. Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukaura, Kanazawa-ku, Yokohama 236-0004, Japan.
3. Division of Immunology, National Center for Child Health and Development, Tokyo, Japan. 4. Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
5. Department of Pediatrics, University of Tokyo Hospital, Tokyo, Japan. 6. Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Received: 8 February 2019 Accepted: 29 May 2019
Published online: 04 June 2019

References

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999;341(17):1284–91.
2. International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335(8697):1078–80.
3. Kinno Y, Bertsias G, Ishigatsubo Y, Miuki N, Tugal-Tutkan I, Seyahi E, Ozyazgan Y, Scali FS, Eer ER, Biko H, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202–7.
4. Badran YR, Dedeoglu F, Leyva Castillo JM, Bainter W, Ohsumi TK, Bouvaros A, Goldsmith JD, Gehr MS, Zhou H. Human RELA haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration. J Exp Med. 2017;214(7):1937–47.
5. Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, Yang D, Demirkaya E, Takeuchi M, Tsai WL, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67–73.
6. Aeschlimann FA, Batu ED, Canna SW, Go E, Gul A, Hoffmann P, Leavis HL, Ozen S, Schwartz DM, Stone DL, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018;77(5):728–35.
7. Berteau F, Rouviere B, Deluc L, Auvray A, Le Berre R, Sanabat Y, Toutou I, de Moreuil C. Autosomic dominant familial Behcet disease and haploinsufficiency A20: a review of the literature. Autoimmune Rev. 2018;17(9):809–15.
8. Franco-Jarava C, Wang H, Martin-Naldina A, Alvarez SD, Garcia-Prat M, Bodet D, Garcia-Patos V, Paja A, Rudilla F, Rodriguez-Sureda V, et al. TNFAIP3 haploinsufficiency is the cause of autoinflammatory manifestations in a patient with a deletion of 13Mb on chromosome 6. Clin Immunol. 2018;191:44–51.
9. Zheng C, Huang Y, Ye Z, Wang Y, Tang Z, Lu J, Wu J, Zhou Y, Wang L, Huang Z, et al. Infantile onset intractable inflammatory bowel disease due to novel heterozygous mutations in TNFAIP3 (A20). Inflamm Bowel Dis. 2018;24(12):2613–20.
10. Takagi M, Ogata S, Ueno H, Yoshida K, Yeh T, Hoshino A, Piao J, Yamashita M, Nanyia M, Okano T, et al. Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2017;139(6):1914–22.
11. Lawless D, Pathak S, Scambler TE, Ouboussad L, Anwar R, Savic S. A case of adult-onset Still’s disease caused by a novel splicing mutation in TNFAIP3 successfully treated with tocilizumab. Front Immunol. 2018;9:1527.
12. Kadokawa T, Ohsimi H, Kawamoto N, Hoil T, Nishimura K, Kobayashi C, Shigemura T, Ogata S, Inoue Y, Kawai T, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol. 2018;141(4):1485–1488.e11.
13. Ohsimi H, Kawamoto N, Seishima M, Ohara O, Fukai T. A Japanese family case with juvenile onset Behcet’s disease caused by TNFAIP3 mutation. Allergol Int. 2017;66(1):146–8.
14. Shigemura T, Kaneo N, Kobayashi N, Kobayashi K, Takeuchi M, Nakano N, Masumoto J, Agematsu K. Novel heterozygous C243Y A20/TNFAP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behcet’s disease. RMD Open. 2016;2(1):e000223.
15. Duncan CIA. Dinnigan E, Theobald R, Grainger A, Skelton AJ, Hussain R, Willett JDP, Swan DJ, Coxhead J, Thomas MF, et al. Early-onset autoimmune
16. Mizushima YIG, Mimura Y, Ono S. Guide for diagnosis of Behçet’s disease. Japan: Report of Behçet’s Disease Research; 1987. p. 8–17.

17. Kihigo Y, Ikeda Y, Takano M, Suda A, Higashihara K, Kunihara Y, Takase-Minegishi K, Tamura M, Watanabe T, Asami Y, et al. Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet’s disease: a retrospective observational study. Arthritis Res Ther. 2016;18(1):217.

18. Iwama K, Iwato A, Shiina M, Mitsuhashi S, Miyatake T, Takata A, Miyake N, Ogata K, Ito S, Mizuguchi T, et al. A novel mutation in SLCTA3 causes episodic ataxia. J Hum Genet. 2018;63(2):207–11.

19. Miyatake S, Koshimiya E, Fujita A, Fukui R, Imagawa E, Ohba C, Kuki I, Nakui M, Araki A, Makita Y, et al. Detecting copy-number variations in whole-exome sequencing data using the eXome Hidden Markov Model: an ‘exome-first’ approach. J Hum Genet. 2015;60(4):175–82.

20. Tsuchida N, Nakashima M, Kato M, Heyman E, Inui T, Haginoya K, Watanabe S, Suyono N, Morimoto M, Ohta M, et al. Detection of copy number variations in epilepsy using exome data. Clin Genet. 2018;93(3):577–87.

21. Fromer M, Moran JL, Chambert K, Banks E, Bergen SE, Ruderfer DM, Handsaker RE, McCarroll SA, O’Donovan MC, et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet. 2012;91(4):597–607.

22. Nord AS, Lee D, King MC, Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics. 2011;12:184.

23. Hug P, Longman D, Caceres JP. Mechanism and regulation of the nonsense-mediated decay pathway. Nucleic Acids Res. 2016;44(4):483–95.

24. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.

25. Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, Bronson RT, Mills AA, Attardi LD. Perp is a p63-regulated gene essential for epithelial integrity. Cell. 2005;120(6):843–56.

26. Ihrie RA, Bronson RT, Attardi LD. Adult mice lacking the p53/p63 target gene Perp are not predisposed to spontaneous tumorigenesis but display features of ectodermal dysplasia syndromes. Cell Death Differ. 2006;13(9):1614–8.

27. Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Clime R, Gattorno M, Anton J, Hofer M, Chikrate B, Bouayed K, et al. Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75(6):958–64.

28. Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, Overton J, Jeffreys E, Kohlha MK, Huttner AJ, et al. Mutation of MLR4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135–9.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions